fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      9   |   10   |   11   |   12   |   13   |   14   |   15   |   16   |   17   |   18   |   19      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-01-11 Qiagen (The Netherlands)
WuXi AppTec (China)
biomarkers R&D
development
other
See details
2010-01-11 AnaptysBio (USA)
Roche (Switzerland)
antibody therapeutics generated with SHM platform
(This platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties.)
R&D
development
See details
2010-01-11 Galapagos (Belgium)

Roche (Switzerland)
new small molecule candidates based on Galapagos's target discovery platform and peptides, siRNA and other nucleic acids. / COPD (chronic obstructive pulmonary disease) R&D
other
See details
2010-01-07 University consortium Combine (Sweden)
Six universities are participating in the consortium: the Karolinska Institute, University,of Uppsala University of Gothneburg, University of Linköping, University of Lund andUniversity of Umeå .
Novo Nordisk (Denmark)
novel therapies for autoimmune diseases.
/ autoimmune diseases
R&D
See details
2010-01-07 Debiopharm (Switzerland)
Pfizer (USA)
tremelimumab (CP675,206), fully human anti-CTLA4 monoclonal antibody / unresectable, Stage IV melanoma commercialization/ distribution
development
See details
2010-01-04 Evolva (Switzerland)
Roche (Switzerland)
compounds with activity on targets in oncology and anti-infectives / cancer
infectious diseases
R&D
See details
2009-12-23
AstraZeneca (UK)
Forest Laboratories (USA)
ceftazidime/NXL-104 (CAZ104) and ceftaroline/NXL-104 (CEF104)

These antibiotic combinations utilise Novexel’s novel investigational beta-lactamase inhibitor NXL-104 to overcome antibiotic-resistance. Under an agreement concluded in January 2008, Novexel granted Forest Laboratories the rights to develop NXL104 in combination with ceftaroline (CEF-104) in North America (See http://www.biopharmaceutiques.com/fr/tables/agreements_257.html)
/ complicated intra-abdominal infections (cIAIs)
complicated urinary tract infections (cUTIs)
skin and diabetic foot infections
commercialization/ distribution
development
See details
2009-12-23 Compugen (Israel)
Pfizer (USA)
therapeutic peptide product candidates will be developed using Compugen’s discovery platforms based on a process of in silico prediction and selection, followed by synthesis and experimental validation. R&D
See details
2009-12-22 Vivalis (France)
undisclosed partner in the veterinary field
  licensing
See details
2009-12-21 OncoGenex (Canada)
Teva Pharmaceutical Industries (Israel)
OGX-011
The product utilizes second-generation antisense technology, licensed from Isis Pharmaceuticals to target and inhibit production of specific proteins. Here the target is clusterin, a protein that is over-produced in several types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. / cancers including advanced prostate cancer and non-small cell lung cancer
licensing
commercialization/ distribution
development
marketing/ promotion
other
See details
2009-12-21 Seattle Genetics (USA)
GSK (UK)
antibody-drug conjugate (ADC) technology R&D
licensing
See details
2009-12-16 Galapagos (Belgium)
GSK (UK)
drug discovery programs based on novel drug target GT622 / arthritis R&D
See details
2009-12-16 Syntiron (USA)
Sanofi Pasteur (France)
vaccine / Staphylococcus infections including MRSA
licensing
commercialization/ distribution
development
See details
2009-12-16 Afferent Pharmaceuticals (USA)
Roche (Switzerland)
P2X3i receptor program / chronic pain licensing
See details
2009-12-15 Femta Pharmaceuticals (USA)
Lonza (Switzerland)
GS (Glutamine Synthetase) Gene Expression System™/FM101 (monoclonal antibody directed against interleukin 6 (IL-6)

/ pre-clinical development
Femta plans to submit an IND (investigational new drug application) and initiate a Phase I clinical trial in 2010.
licensing
manufacturing
See details
[<<]      «      9   |   10   |   11   |   12   |   13   |   14   |   15   |   16   |   17   |   18   |   19      »      [65]